 CARLSBAD, Calif., Oct. 19, 2021 GLOBE NEWSWIRE -- Qualigen Therapeutics, Inc. Nasdaq: QLGN, a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the publication of a study in the peer-reviewed, open-source journal, Diagnostics, validating the Companys point of care FastPack IP FastPack diagnostic test as comparable to an industry-leading laboratory method in determining thyroid stimulating hormone TSH levels in blood. 